This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Brittain, R. T. Articles by Jack, D. Search for Related Content PubMed PubMed Citation Articles by Brittain, R. T. Articles by Jack, D. Pubmed/NCBI databases Compound via MeSH Substance via MeSH

Circulation, Vol 72, 1208-1218, Copyright © 1985 by American Heart Association

ARTICLES

AH23848: a thromboxane receptor-blocking drug that can clarify the pathophysiologic role of thromboxane A2

RT Brittain, L Boutal, MC Carter, RA Coleman, EW Collington, HP Geisow, P Hallett, EJ Hornby, PP Humphrey and D Jack

Despite numerous suggestions in the literature that thromboxane A2 is involved in a variety of occlusive vascular diseases, no definitive evidence is available. Arguments have been presented to support the view that such evidence can only come from clinical studies with a highly specific thromboxane receptor-blocking drug. We have now identified such a drug, AH23848, in our laboratories. Preliminary experiments with AH23848, ([1 alpha (Z), 2 beta,5 alpha]-(+/-)-7-[5- [[(1,1'-biphenyl)-4-yl]methoxy]-2-(4-morpholin yl)-3-oxocyclopentyl]-4- heptenoic acid), show that it is a potent, specific thromboxane receptor-blocking drug that is orally active and has a long duration of action. It should be a valuable tool in elucidating any physiologic or pathologic role of thromboxane A2.